Bambusa Taps Veteran CFO Todd James to Fuel Ambitious I&I Pipeline

BOSTON, MA – March 19, 2026 – Bambusa Therapeutics, a clinical-stage company developing next-generation antibodies for inflammatory diseases, has appointed Todd James as its new Executive Vice President and Chief Financial Officer. The strategic hire brings a seasoned financial executive with a history of significant capital raises and a multi-billion-dollar corporate acquisition to the helm of Bambusa's finances, signaling a clear intent to accelerate its growth and advance its ambitious clinical pipeline.

Mr. James joins the Boston-based biotech at a pivotal moment. Founded just two years ago in 2024, Bambusa has rapidly progressed its lead candidates into clinical trials and secured substantial backing from top-tier investors. The appointment is seen as a move to bolster its executive team with the financial expertise needed to navigate the demanding path from clinical development to potential commercialization.

A Strategic Play for Financial Firepower

Todd James is not a typical CFO hire for an early-stage company. He brings more than two decades of senior leadership experience in the biopharmaceutical industry, with a resume that includes key roles at two high-profile public companies, Acceleron Pharma and Viridian Therapeutics. His tenure at Acceleron, from 2015 until its $11.5 billion acquisition by Merck in 2021, is particularly notable. There, he established and led the investor relations and corporate affairs functions, playing a crucial role in strategic financing activities that collectively raised over $1 billion through four separate offerings.

His success in communicating company value and strategy to the financial community was recognized by Institutional Investor magazine, which named him the Best Investor Relations Professional in Biotechnology for three consecutive years from 2019 to 2021. This track record is precisely what a company like Bambusa needs as it looks to secure its financial future.

"We are thrilled to welcome Todd to Bambusa as our Chief Financial Officer," said Dr. Shanshan Xu, Founder and Chief Executive Officer of Bambusa Therapeutics, in a statement. "Todd brings a proven track record of capital markets execution and strategic leadership. Having had the opportunity to engage with him in my time as a research analyst—and most recently benefiting from his collaboration as a senior advisor to Bambusa—I have seen firsthand his ability to support long-term value creation."

Dr. Xu highlighted that James's appointment comes as the company advances toward its ambitious '2+2 vision,' a plan that requires significant capital and strategic financial planning to execute.

Fueling the '2+2 Vision' for Novel I&I Therapies

The '2+2 vision' is Bambusa’s aggressive corporate goal for 2028: advancing its two lead bispecific antibodies, BBT001 and BBT002, into pivotal studies while moving its next two preclinical programs, BBT003 and BBT004, into proof-of-concept clinical trials. This rapid development timeline is a hallmark of the company, which has already demonstrated an ability to move at an impressive pace.

Bambusa’s pipeline is built on an innovative antibody engineering platform designed to create bispecific antibodies—single molecules that can hit two therapeutic targets at once. The platform also incorporates half-life extension technology for less frequent dosing and is designed for high-concentration subcutaneous delivery.

• BBT001, its lead candidate for atopic dermatitis, entered Phase 1 trials in March 2025. By September of that year, the company had already presented positive initial data from healthy volunteers showing a favorable safety profile and a half-life of approximately 33 days, suggesting the potential for monthly or less frequent dosing. The first patients with atopic dermatitis were dosed later that month.

• BBT002 is described as a potential 'platform-in-a-molecule,' targeting two key pathways in Type 2 inflammation. It is being developed for a wide range of conditions, including COPD, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The program entered the clinic in May 2025, and the first patient with COPD was dosed in a Phase 1b trial in January 2026.

Advancing these two programs to pivotal trials—the large, late-stage studies required for regulatory approval—by 2028 is a demanding objective. It will necessitate flawless execution and, critically, the financial resources to fund these expensive studies. Simultaneously, the company plans to push its preclinical assets in gastroenterology (BBT003) and rheumatology (BBT004) into human trials, a goal supported by a recent Series A-2 financing round.

Navigating a Competitive and Evolving Biotech Landscape

Bambusa's move to bring in a financial heavyweight like James is also a reflection of the broader biotech market in early 2026. After a challenging downturn in 2025, the funding environment has become cautiously optimistic but highly selective. Investors are placing their bets on companies with differentiated science, strong clinical data, and—perhaps most importantly—an experienced management team capable of navigating market volatility and executing on a clear strategy.

Securing top-tier executive talent has become a critical battleground for emerging biotechs. By hiring James, Bambusa not only gains his expertise but also sends a powerful signal of confidence to the investment community. The company has already been successful in this arena, having raised a total of $143 million since its 2024 inception from a syndicate of blue-chip investors including RA Capital Management, BVF Partners, and an investment platform controlled by KKR.

The immunology and inflammation (I&I) space itself is both highly promising and intensely competitive. While large pharmaceutical companies and other biotechs are also developing bispecific antibodies, significant unmet needs persist for patients with chronic conditions like atopic dermatitis. Bambusa aims to carve out a leadership position by developing therapies that offer enhanced efficacy and convenience over existing treatments.

Mr. James acknowledged the opportunity in his own statement. "Shanshan and the Bambusa team have built a differentiated biopharmaceutical company focused on the I&I space, anchored by a platform of bispecific antibodies designed to engage complementary, validated therapeutic targets," he said. "I am excited to partner with the team to further strengthen Bambusa's financial strategy and external engagement as we advance the Company's mission to deliver transformative medicines."

With a seasoned financial architect now on its executive team, Bambusa Therapeutics appears well-equipped to build on its early momentum and fund its ambitious journey to redefine treatment for chronic inflammatory diseases.